8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                -----------------

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of the earliest event reported): November 16, 2007

                                  Aspyra, Inc.
             (Exact Name of Registrant as Specified in Its Charter)

    California                       0-12551                    95-3353465
  (State or Other                  (Commission                 (IRS Employer
  Jurisdiction of                  File Number)             Identification No.)
  Incorporation)

                               26115-A Mureau Road
                               Calabasas, CA 91302
               (Address of Principal Executive Offices) (Zip Code)

                                 (818) 880-6700
              (Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






Item 2.02         Results of Operations and Financial Condition.

         On November 16, 2007, Aspyra, Inc. issued a press release announcing
its operating and financial results for the third fiscal quarter ended September
30, 2007. A copy of the Press Release is attached hereto as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.

         The information in this Current Report on Form 8-K and the Exhibits
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they
be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.

Item 9.01         Financial Statements and Exhibits.


         (c) Exhibits.

Exhibit
Number                          Description of Exhibit
- ----------  --------------------------------------------------------------------

  99.1      Aspyra, Inc. Press Release issued November 16, 2007.






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


November 16, 2007                       Aspyra, Inc.

                                           /s/ Anahita Villafane
                                        ----------------------------------------
                                           Anahita Villafane
                                           Chief Financial Officer and Secretary





                                  EXHIBIT INDEX

Exhibit
Number                          Description of Exhibit
- ----------  --------------------------------------------------------------------

  99.1      Aspyra, Inc. Press Release issued November 16, 2007.

EX-99.1

                                                                    Exhibit 99.1

             Aspyra Reports Results of Operations for the
                Third Quarter Ended September 30, 2007


    CALABASAS, Calif.--(BUSINESS WIRE)--Nov. 16, 2007--Aspyra, Inc.
(AMEX:APY), a provider of clinical and diagnostic information systems
for the healthcare industry, today reported its results of operations
for the third quarter ended September 30, 2007.

    Sales were $2,892,925 for the third quarter compared with sales of
$3,282,041 for the comparable quarter ended September 30, 2006. The
Company incurred a net loss of $1,461,784 for the quarter ended
September 30, 2007, compared to a net loss of $710,063 for the quarter
ended September 30, 2006. For the quarter ended September 30, 2007,
basic and diluted loss per share was $.13, compared with basic and
diluted loss per share of $.07 for the comparable quarter ended
September 30, 2006. Basic and diluted shares outstanding for each
period were 11,337,150 and 10,772,914, respectively.

    Sales were $7,745,550 for the nine months ended September 30,
2007, compared with sales of $9,201,937 for the nine months ended
September 30, 2006. The Company incurred a net loss of $3,670,697, or
basic and diluted loss per share of $.33 for the nine months ended
September 30, 2007 compared with a net loss of $3,087,961 or basic and
diluted loss per share of $.32 for the comparable nine-month period
ended September 30, 2006. Basic and diluted shares outstanding for
each period were 10,969,594 and 9,625,505, respectively.

    James R. Helms, Chief Operating Officer, stated, "Although the
Deficit Reduction Act (DRA) initially had caused a certain slowdown in
the healthcare imaging industry, we expect to see an upswing in sales
due to the productivity tools available within our imaging solutions.
We continue our efforts to restore top line growth by delivering
enhanced value to our customers. With the recent enhancements to our
products, including Mammography viewing within our PACS solution, and
Windows platform for our RIS and LIS products, we expect to see an
increase in new sales and upgrades in the upcoming quarters."

    Aspyra is a global provider of Health Care Information Technology
(HCIT) solutions and services to the healthcare industry. The Company
specializes in Clinical Information Systems (CIS), Picture Archive
Communication Systems (PACS) and Clinical Image Management Systems
(CIMS) for hospitals, multi-specialty clinics, clinical laboratories,
imaging departments and centers and orthopedic environments. Aspyra's
highly scalable systems can be installed standalone or integrated to
provide a single-vendor, enterprise-wide solution. For more
information on Aspyra, its products and services, visit
www.aspyra.com.

    Safe Harbor Statement

    This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements related to anticipated revenues, expenses,
earnings, operating cash flows, the outlook for Aspyra's markets and
the demand for its products. Forward-looking statements are not
guarantees of future performance and are inherently subject to
uncertainties and other factors which could cause actual results to
differ materially from the forward-looking statement. Such statements
are based upon, among other things, assumptions made by, and
information currently available to, management as of today November
16, 2007, including management's own knowledge and assessment of the
Company's industry and competition. Factors that could cause Aspyra's
actual results to differ materially from these forward-looking
statements include among others: whether the combined company will
realize the potential benefits of the merger; the competitive
environment; unexpected technical and marketing difficulties inherent
in major product development efforts; the potential need for changes
in our long-term strategy in response to future developments; future
advances in clinical information technology and procedures, as well as
potential changes in government regulations and healthcare policies;
and rapid technological change in the microelectronics and software
industries. The Company refers interested persons to its most recent
Annual Report on Form 10-KSB and its other SEC filings for a
description of additional uncertainties and factors, which may affect
forward-looking statements. The Company assumes no duty to update its
forward-looking statements.



                 Consolidated Statement of Operations

                     Third Quarter Ended        Nine Months Ended
                         September 30,             September 30,

                       2007         2006         2007         2006
                    ----------   ----------   ----------   ----------

Net Sales          $ 2,892,925  $ 3,282,041  $ 7,745,550  $ 9,201,937

Net Loss           $(1,461,784) $  (710,063) $(3,670,697) $(3,087,961)
Net Loss per Share
 - Basic and
 Diluted           $     (0.13) $     (0.07) $     (0.33) $     (0.32)
Average Shares
 Outstanding--
 Basic and Diluted  11,337,150   10,772,914   10,969,594    9,625,505



    CONTACT: Aspyra, Inc.
             Michelle Del Guercio
             Director of Marketing
             818-880-6700 x8688